SCHEMBL4933069

SCHEMBL4933069

Cc1ccc(-c2cc(C(=O)N3CCC(F)(F)CC3)nn2-c2ccccn2)nc1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 2/20 0.42
CYP3A4 P08684 6/20 0.42
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 8/20 0.41
TSHR P16473 3/20 0.41
CYP2D6 P10635 5/20 0.41
CYP2C19 P33261 1/20 0.41
KDM1A O60341 2/20 0.40
HPGD P15428 4/20 0.39
HSD17B10 Q99714 5/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
CYP2C9 P11712 2/20 0.39
CYP1A2 P05177 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
GRM5 P41594 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4932861 0.89 HTR1A (0.42) HTR1ACYP3A4ALDH1A1CYP2D6KDM1A
SCHEMBL4933853 0.89 HTR1A (0.40) HTR1AKDM1ATDP1GRM5
SCHEMBL4934939 0.89 CYP3A4 (0.40) HTR1ACYP3A4ALDH1A1CYP2D6CYP2C19
SCHEMBL4931213 0.88 CYP3A4 (0.40) HTR1ACYP3A4KDM4EALDH1A1TSHR
SCHEMBL4932943 0.88 ALDH1A1 (0.42) KDM4EALDH1A1TSHRKDM1AHPGD
SCHEMBL5273124 0.85 KDM1A (0.40) HTR1AKDM1AHPGDTDP1GRM5
SCHEMBL4931684 0.84 KDM1A (0.43) HTR1ACYP3A4CYP2C19KDM1ASMN1; SMN2
SCHEMBL4927931 0.81 MARS1 (0.52) KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL2916627 0.78 ABL1 (0.38) CYP3A4ALDH1A1TSHRCYP2D6CYP2C19
SCHEMBL4931270 0.77 CYP3A4 (0.40) CYP3A4ALDH1A1CYP2D6CYP2C19HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080064682-A1 Pyrazole Derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-03-13 US disclosed
US-20080064682-A1 Pyrazole Derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-03-13 US disclosed
US-20080064682-A1 Pyrazole Derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-03-13 US disclosed
CN-1980912-A Pyrazole derivatives DAIICHI SEIYAKU CO (JP) 2007-06-13 CN disclosed
EP-1762568-A1 PYRAZOLE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-03-14 EP disclosed
EP-1762568-A1 PYRAZOLE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-03-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064682-A1 Pyrazole Derivatives NAT1, AR, CBR3 HTR1A 362/4885CYP3A4 65/4885KDM4E 2256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.